Latest News | Indian Immunologicals Receives Regulatory Approval for Measles-Rubella Vaccine

Hyderabad, Mar 27 (PTI) Indian Immunologicals Limited (IIL), a city-based vaccine maker on Monday announced receipt of approval from Drugs Controller General of India and State Drug Control Administration for manufacturing of Measles-Rubella (MR) Vaccine.

Also Read | Adani Group Firms End Lower; Adani Power, Adani Transmission Fall Nearly 5%.

A press release from IIL said, "IIL's Indo-Vietnam Partnership resulted in manufacturing and marketing authorisation of their Measles-Rubella (MR) Vaccine. IIL partnered with Center for Research and Production of Vaccines and Biologicals, also called Polyvac, Vietnam".

Also Read | India's Heat Action Plans Not Suited to Risks, Says Report.

Under an exclusive agreement, Polyvac, Vietnam will supply the Measles vaccine component to IIL. Rubella Vaccine component will be produced by IIL to manufacture a combined MR vaccine, it said.

This Live Attenuated MR vaccine adds to the list of several other vaccines that IIL supplies to Universal Immunization Programme (UIP) of India, the release said.

This vaccine has been proven through extensive human clinical trials to be immunogenic and safe for people of 9 months to 49 years, it said.

K Anand Kumar, Managing Director, Indian Immunologicals Limited said, "We have successfully completed all phases of product development to the satisfaction of the regulatory authorities in India. Measles-Rubella (MR) vaccine is listed in the UIP of India and is an important vaccine for our country."

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)